Managing cardiovascular risk in minority patients

Journal of the National Medical Association

Volumn 97, Issue 4, 2005, Pages 459-466

  Ferdinand, Keith C ^a,b  

^a Heartbeats Life Center ^*

^b Heartbeats Life Center   (United States)

Author keywords

African Americans; Cardiovascular disease; Coronary heart disease; Hispanics; Risk factors; South Asians; Statins

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STATINE DERIVATIVE;

ADOLESCENT; ADULT; AFRICAN AMERICAN; AGED; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS; DISEASE PREDISPOSITION; DYSLIPIDEMIA; FEMALE; HISPANIC; HUMAN; HYPERTENSION; MALE; MINORITY GROUP; OBESITY; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK MANAGEMENT; RISK REDUCTION; SCHOOL CHILD; SCREENING; SOUTH ASIA; UNITED STATES;

ADOLESCENT; ADULT; AFRICAN AMERICANS; AGE DISTRIBUTION; AGED; ASIAN AMERICANS; CARDIOVASCULAR DISEASES; CORONARY DISEASE; FEMALE; HISPANIC AMERICANS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; INCIDENCE; LIFE STYLE; MALE; MIDDLE AGED; MINORITY GROUPS; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SURVIVAL ANALYSIS; UNITED STATES;

EID: 16244406200     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. American Heart Association. Heart Disease and Stroke Statistics-2004 Update. Dallas, TX: American Heart Association; 2003.
2. Clark LT, Ferdinand KC, Flack JM, et al. Coronary heart disease in African Americans. Heart Dis. 2001;3:97-108.
3. Pandey DK, Labarthe DR, Goff DC, et al. Community-wide coronary heart disease mortality in Mexican Americans equals or exceeds that in non-Hispanic whites: the Corpus Christi Heart Project. Am J Med. 2001;110:81-87.
4. Gupta R, Gupta VP, Sarna M, et al. Prevalence of coronary heart disease and risk factors in an urban Indian population: Jaipur Heart Watch-2. Indian Heart J. 2002;54:59-66.
5. Bhopal R. Epidemic of cardiovascular disease in South Asians: prevention must start in childhood. BMJ. 2002;324:625-626.
6. Gupta R, Vasisht S, Bahl VK, et al. Correlation of lipoprotein(a) to angiographically defined coronary artery disease in Indians. Int J Cardiol. 1996;57:265-270.
7. Enas EA, Yusuf S, Sharma S. Coronary artery disease in South Asians: second meeting of the International Working Group: 16 March 1997, Anaheim, CA. Indian Heart J. 1998;50:105-113.
8. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
9. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among U.S. adults: findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.
10. The Expert Panel. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation. 2002;106:3143-3421.
11. Misra A, Vikram NK. Insulin resistance (metabolic syndrome) and obesity in Asian Indians: evidence and implications. Nutrition. 2004;20:482-491.
12. Brancati FL, Kao WH, Folsom AR, et al. Incident type-2 diabetes mellitus in African-American and white adults: the Atherosclerosis Risk in Communities Study. JAMA. 2000;283:2253-2259.
13. Cook DG, Mendall MA, Whincup PH, et al. C-reactive protein concentration in children: relationship to adiposity and other cardiovascular risk factors. Atherosclerosis. 2000;149:139-150.
14. Das UN. Metabolic syndrome X is common in South Asians, but why and how? Nutrition. 2002;18:774-776.
15. Enas EA, Davidson MH, Nair V, et al. Prevalence of coronary heart disease (CHD) and its risk factors in Asian Indian migrants to the United States. Indian Heart J. 1996;48:343-353.
16. Freid VM, Prager K, MacKay AP, et al. Chartbook on Trends in the Health of Americans. Health, United States: 2003. Hyattsville, MD: National Center for Health Statistics; 2003.
17. Gupta M, Doobary AV, Singh N, et al. Risk factors, hospital management and outcomes after acute myocardial infarction in South Asian Canadians and matched control subjects. CMAJ. 2002;166:717-722.
18. Haffner SM, Morales PA, Hazuda HP, et al. Level of control of hypertension in Mexican Americans and non-Hispanic whites. Hypertension. 1993; 21:83-88.
19. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance in U.S. adults: the Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Core. 1998;21:518-524.
20. Hutchinson RG, Watson RL, Davis CE, et al. Racial differences in risk factors for atherosclerosis: the ARIC Study. Angiology. 1997;48:279-290.
21. Mitchell BD, Stern MP, Haffner SM, et al. Risk factors for cardiovascular mortality in Mexican Americans and non-Hispanic whites: San Antonio Heart Study. Am J Epidemiol. 1990;131:423-433.
22. Tortolero SR, Goff Jr DC, Nichama MZ, et al. Cardiovascular risk factors in Mexican-American and non-Hispanic white children: the Corpus Christi Child Heart Study. Circulation. 1997;96:418-423.
23. Wei M, Mitchell BD, Haffner SM, et al. Effects of cigarette smoking, diabetes, high cholesterol and hypertension on all-cause mortality and cardiovascular disease mortality in Mexican Americans: the San Antonio Heart Study. Am J Epidemiol. 1996;144:1058-1065.
24. Winkleby MA, Robinson TN, Sundquist J, et al. Ethnic variation in cardiovascular disease risk factors among children and young adults: findings from the Third National Health and Nutrition Examination Survey, 1988-1994. JAMA. 1999;281:1006-1013.
25. Jones DW, Chambless LE, Folsom AR, et al. Risk factors for coronary heart disease in African Americans: the Atherosclerosis Risk in Communities Study, 1987-1997. Arch Intern Med. 2002;162:2565-2571.
26. Liao Y, Cooper RS, Cao G, et al. Mortality from coronary heart disease and cardiovascular disease among adult U.S. Hispanics: findings from the National Health Interview Survey (1986-1994). J Am Coll Cardiol. 1997;30; 1200-1205.
27. Klatsky AL, Tekawa I, Armstrong MA, et al. Asian Americans born in India and Pakistan are at high risk of coronary disease hospitalizatian. Am J Public Health. 1994;84:1672-1675.
28. Mohan V, Deepa R, Haranath SP, et al. Lipoprotein(a) is an independent risk factor for coronary artery disease in NIDDM patients in South India. Diabetes Care. 1998;21:1819-1823.
29. McKeigue PM, Shah B, Marmot MG. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. Lancet. 1991;337:971-993.
30. Anand SS, Enas EA, Pogue J, et al. Elevated lipoprotein(a) levels in South Asians in North America. Metabolism. 1998;47:182-189.
31. qhandalia M, Cabo-Chan Jr AV, Devaraj S, et al. Elevated plasma high-sensitivity C-reactive protein concentrations in Asian Indians living in the United States. J Clin Endocrinol Metab. 2003;88:3773-3776.
32. Ogden CL, Flegal KM, Carroll MD, et al. Prevalence and trends in overweight among U.S. children and adolescents, 1999-2000. JAMA. 2002;288: 1772-1773.
33. Muntner P, He J, Cutler JA, et al. Trends in blood pressure among children and adolescents. JAMA. 2004;291:2107-2113.
34. Ferdinand KC. Coronary heart disease and lipid-modifying treatment in African-American patients. Am Heart J. 2004;147:774-782.
35. Cook CB, Erdman DE, Ryan GJ, et al. The pattern of dyslipidemia among urban African Americans with type-2 diabetes. Diabetes Care. 2000;23:319-324.
36. Haffner SM, Gruber KK, Morales PA, et al. Lipoprotein(a) concentrations in Mexican Americans and non-Hispanic whites: the San Antonio Heart Study. Am J Epidemiol. 1992;136:1060-1068.
37. Rodriguez C, Pablos-Mendez A, Palmas W, et al. Comparison of modifiable determinants of lipids and lipoprotein levels among African Americans, Hispanics and non-Hispanic Caucasians ≥65 years of age living in New York City. Am J Cardiol. 2002;89:178-183.
38. Nelson K, Norris K, Mangione CM. Disparities in the diagnosis and pharmacologic treatment of high-serum cholesterol by race and ethnicity: dota from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2002;162:929-935.
39. Jha AK, Varosy PD, Kanaya AM, et al. Differences in medical care and disease outcomes among black and white women with heart disease. Circulation. 2003;108:1089-1094.
40. Nieto FJ, Alonso J, Chambless LE, et al. Population awareness and control of hypertension and hypercholesterolemia: the Atherosclerosis Risk in Communities Study. Arch Intern Med. 1995;155:677-684.
41. Flack JM, Ferdinand KC, Nasser SA. Epidemiology of hypertension and cardiovascular disease in African Americans. J Clin Hypertens (Greenwich). 2003;5(suppl 1):5-11.
42. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
43. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
44. Sacks FM, Pfeffer MA, Moyé LA, et al for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
45. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
46. Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
47. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized, placebo-controlled trial. Lancet. 2002;360:7-22.
48. LaRosa JC, Applegate W, Crouse III JR, et al. Cholesterol lowering in the elderly: results of the Cholesterol Reduction in Seniors Program (CRISP) pilot study. Arch Intern Med. 1994;154:529-539.
49. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)JAMA. 2002;288:2998-3007.
50. Brown WV, Moussa M. Perspectives from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial-Lipid-Lawering Trial and the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm. Curr Opin Lipidol. 2003;14:593-597.
51. Pasternak RC. The ALLHAT Lipid-Lowering Trial: less is less. JAMA. 2002;288:3042-3044.
52. Bild DE, Bluemke DA, Burke GL, et al. Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol. 2002;156:871-881.
53. Ferdinand K, Deedwania PC, Haffner S, et al. Designs of three trials comparing rosuvastatin and atorvastatin in African-American, South Asian and Hispanic patients: ARIES, IRIS and STARSHIP trials. Poster presented at the International Symposium on Atherosclerosis: Kyoto, Japan; September 28-October 2, 2003.
54. Blasetto JW, Stein EA, Brown WV, et al. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am J Cardiol. 2003;91 (suppl): 3C-10C.
55. Shepherd J, Hunninghake DB, Barter P, et al. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin and simvastatin for achieving lipid-lowering goals. Am J Cardiol. 2003;91(suppl):11C-19C.
56. Flack JM, Victor R, Watson K, et al. Rationale and design of the CAPABLE study: an investigation into the use of amlodipine/atorvastatin single-pill dual therapy in the treatment of African-American patients with concomitant hypertension and dyslipidemia. Poster presented at the 19th Annual International Society on Hypertension in Blacks (ISHIB) conference; Detroit, MI; June 13-16, 2004.